CN105079076A - Pharmaceutical composition for the treatment of adult growth hormone deficiency syndrome - Google Patents
Pharmaceutical composition for the treatment of adult growth hormone deficiency syndrome Download PDFInfo
- Publication number
- CN105079076A CN105079076A CN201410200379.0A CN201410200379A CN105079076A CN 105079076 A CN105079076 A CN 105079076A CN 201410200379 A CN201410200379 A CN 201410200379A CN 105079076 A CN105079076 A CN 105079076A
- Authority
- CN
- China
- Prior art keywords
- medical composition
- growth hormone
- treatment
- adult
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 10
- 206010056438 Growth hormone deficiency Diseases 0.000 title abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims description 29
- 239000000843 powder Substances 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 10
- 241001416980 Paecilomyces hepiali Species 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000013402 health food Nutrition 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 241000208340 Araliaceae Species 0.000 claims description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 235000008434 ginseng Nutrition 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 229960003080 taurine Drugs 0.000 claims description 5
- 241000005787 Cistanche Species 0.000 claims description 4
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 4
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 4
- 239000000854 Human Growth Hormone Substances 0.000 claims description 4
- 239000007937 lozenge Substances 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 241001165494 Rhodiola Species 0.000 abstract 1
- 244000042430 Rhodiola rosea Species 0.000 abstract 1
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 description 17
- 108010051696 Growth Hormone Proteins 0.000 description 17
- 239000000122 growth hormone Substances 0.000 description 16
- 230000033001 locomotion Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 241000190633 Cordyceps Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000035611 feeding Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010054196 Affect lability Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000336316 Cistanche tubulosa Species 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 101000868151 Rattus norvegicus Somatotropin Proteins 0.000 description 1
- 241000997135 Rhodiola crenulata Species 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000009578 growth hormone therapy Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a pharmaceutical composition for treating adult growth hormone deficiency syndrome, which mainly comprises Rhodiola rosea (Rhodiola.
Description
Technical field
The present invention is about a kind of medical composition being used for the treatment of the not enough syndrome of Adult GH.
Background technology
The synthetic hormone (anabolichormone) that growth hormone (GH) is human secretory, has the functions such as the repairing promoting muscular strength development, muscle growth and protein synthesis and promote wounded tissue.Use growth hormone treat the growth hormone deficiency of adult clinically, and use growth hormone therapy show and can reduce fat, increase muscle strength and improve sclerotin.In addition, the secretory volume of human growth hormone increases along with the age and lowers, and therefore, also has with somatotropin prolonged aging correlational study.
Adult growth hormone deficiency mainly causes body weight increases, lipotrophy, muscle minimizings, bone-loss, motor capacity is not enough, overall energy low, cardiovascular disease increases, the lost of life, immune depression, xerosis cutis, cold-resistant, metabolism reduces, have a sleepless night, HDL-C lowly, the symptom such as attention cannot concentrate, forgetful and emotional instability, be generally referred to as Adult GH's deficiency syndrome.
So, the side effect that long term injections growth hormone is possible comprises: arthroncus, arthralgia, Carpel Tunnel Syndrome, and the risk having increase diabetes.
The invention provides a kind of medical composition, it can promote that human growth hormone secretes, and for the manufacture for the treatment of the medicament of the not enough syndrome of Adult GH.This medical composition mainly comprises Radix Rhodiolae and Cordyceps two kinds of compositions, known Radix Rhodiolae and Cordyceps two kinds of Chinese herbal medicine for having allaying tiredness, prevent high mountain disease, anti-inflammatory and reduce the effects such as free radical.
Summary of the invention
The object of this invention is to provide one and be used for the treatment of the not enough syndrome medical composition of Adult GH, comprise Radix Rhodiolae and Cordyceps.In specific words, medical composition of the present invention comprises: Radix Rhodiolae (Rhodiolacrenulata) extract of 50 to 95 % by weight, and the Paecilomyces hepiali Chen et Dai Mycelia of 5 to 50 % by weight (PaecilomyceshepialaChenetDaimycelia) powder.
Medical composition of the present invention can comprise Herba Cistanches (Cistanchetubulosa), Radix Et Caulis Acanthopanacis Senticosi (SiberianGinseng), taurine (Taurine) and Radix Ginseng further and concentrate powder (Ginseng); Further can comprise pharmaceutically acceptable excipient, this excipient can be selected from one of magnesium stearate and silicon dioxide or many persons.
Another object of the present invention is to provide and a kind ofly utilizes above-mentioned medical composition manufacture to treat the not enough medicament of syndrome of Adult GH or the purposes of health food.
Another object of the present invention is to provide a kind of purposes utilizing above-mentioned medical composition manufacture to promote the medicament that human growth hormone secretes or health food.
Medicament of the present invention and health food are oral dosage form, and it can be lozenge, capsule or powder.
Accompanying drawing explanation
Fig. 1 is the flow chart preparing Radix Rhodiolae extract of the present invention.
Fig. 2 is the flow chart preparing Paecilomyces hepiali Chen et Dai Mycelia powder of the present invention.
Fig. 3 shows rat growth hormone concentration change situation in (Post-ex) and convalescent blood after (Pre-ex), motion before motion.
Detailed description of the invention
Prepare medical composition of the present invention
Medical composition of the present invention mainly comprises Radix Rhodiolae extract and Paecilomyces hepiali Chen et Dai Mycelia powder.The preparation of this Radix Rhodiolae extract with reference to the flow chart of Fig. 1, by Radix Rhodiolae greenwood through pulverizing, extraction, after concentrated and lyophilization, then through levigation and sieve to make.Through further check analysis, in this Radix Rhodiolae extract containing have an appointment 1% rhodioside (salidroside) index components.Separately, the preparation of this Paecilomyces hepiali Chen et Dai Mycelia powder with reference to the flow chart of Fig. 2, by peacilomyce hepiahi bacterium strain through cultivating and fermentation, gained mycelium again through freezing or bake drying, grind and sieve to make.In addition, the medical composition of the present invention further comprises Herba Cistanches, taurine and Radix Ginseng and concentrates powder; And further can comprise pharmaceutically acceptable excipient, this excipient can be selected from one of magnesium stearate and silicon dioxide or many persons.Medical composition of the present invention comprises the Paecilomyces hepiali Chen et Dai Mycelia powder of 50 to 95 % by weight Radix Rhodiolae extracts and 5 to 50 % by weight.Medical composition of the present invention is preferably makes lozenge, such as, in the 600mg lozenge made with medical composition of the present invention, comprises the Radix Rhodiolae extract of 420mg and the Paecilomyces hepiali Chen et Dai Mycelia powder of 180mg.
The test of medical composition growth promoting effects hormone secretion of the present invention
According to research, after high strength or prolonged exercise, the change of hormonal system and regulation and control motor fitness phenomenon will be brought out.Therefore, by hormone concentration change after measurement motion, the effect of medical composition growth promoting effects hormone secretion of the present invention is analyzed.
Use SpragueDawley (SD) rat of 40 body weight about 250 grams, be divided into according to body weight matching method: placebo group (control group, n=10), dosage is 124mg/kg (n=10), 248mg/kg (n=10) and 744mg/kg (n=10).The every day same time gives the medical composition of the present invention of a relative body weight dosage in supply bobbin mode, continuous feeding 10 days.This test use medical composition to comprise each composition and content as shown in the table:
| Composition | Mg/ ingot | ％ |
| Radix Rhodiolae extract | 480 | 80.0 |
| Herba Cistanches | 42 | 7.0 |
| Paecilomyces hepiali Chen et Dai Mycelia powder | 36 | 6.0 |
| Radix Et Caulis Acanthopanacis Senticosi | 18 | 3.0 |
| Taurine | 18 | 3.0 |
| Radix Ginseng concentrates powder | 6 | 1.0 |
| Subtotal | 600 | 100.0 |
Measure (Pre-ex) before moving after (baseline), continuous seven days feedings before feeding respectively, extremely exhaustion rear (Post-ex), the tail challenging four time points of rear convalescent period that moves take growth hormone concentration change in blood sample to implement single motion challenge in treadmill mode every other day.
Get 400 μ l blood plasma after blood sample is centrifugal, use growth hormone reagent (Millipore, Billerica, USA) to analyze growth hormone concentration with TECANGeniosELISAanalyzer (Salzburg, Austria).With the variable of two factor repeated-measures analysis mode (Two-wayanalysisofvariancewithrepeatedmeasures) more each time points, recycling independent sample t-test compares the difference measuring variable between various dose group.Numerical value presentation mode is average ± standard error (mean ± SE), notable level Wei α≤0.05.
The result of growth hormone change refers to Fig. 3, after within continuous seven days, taking 124mg/kg dosage, growth hormone concentration before motion in (Pre-ex) blood is significantly higher than control group and reaches 12 times, the concentration no significant difference of (Post-ex) four groups after the challenge of single Exhaustive exercise; So, in convalescent 124mg/kg dosage group higher than control group 6 times; 248mg/kg dosage group is higher than control group 10 times; And 744mg/kg dosage group is higher than control group 5 times.Show medical composition of the present invention and can effectively improve growth hormone concentration, the secretion of growth promoting effects hormone, the associated conditions for growth hormone deficiency has therapeutic effect.
Above-mentioned preferred embodiment is only and illustrates, not for limiting the present invention, be familiar with the art person according to above-mentioned explanation make different changes, all belong to scope of the present invention.
Claims (7)
1. be used for the treatment of the not enough syndrome medical composition of Adult GH, comprise the Radix Rhodiolae extract of 50 to 95 % by weight, and the Paecilomyces hepiali Chen et Dai Mycelia powder of 5 to 50 % by weight.
2. medical composition as claimed in claim 1, it comprises Herba Cistanches, Radix Et Caulis Acanthopanacis Senticosi, taurine and Radix Ginseng further and concentrates powder.
3. medical composition as claimed in claim 1 or 2, it comprises pharmaceutically acceptable excipient further, and it one of to be selected from magnesium stearate and silicon dioxide or many persons.
4. medical composition as claimed in claim 1, wherein, this Radix Rhodiolae extract containing have an appointment 1% rhodioside.
5. a purposes for the medical composition according to any one of Claims 1 to 4, its medicament for the manufacture of the not enough syndrome for the treatment of Adult GH or health food.
6. a purposes for the medical composition according to any one of Claims 1 to 4, it is for the manufacture of the medicament or the health food that promote human growth hormone's secretion.
7. the purposes as described in claim 5 or 6, wherein, this medicament or health food are the oral dosage form of lozenge, capsule or powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410200379.0A CN105079076A (en) | 2014-05-13 | 2014-05-13 | Pharmaceutical composition for the treatment of adult growth hormone deficiency syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410200379.0A CN105079076A (en) | 2014-05-13 | 2014-05-13 | Pharmaceutical composition for the treatment of adult growth hormone deficiency syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105079076A true CN105079076A (en) | 2015-11-25 |
Family
ID=54561007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410200379.0A Pending CN105079076A (en) | 2014-05-13 | 2014-05-13 | Pharmaceutical composition for the treatment of adult growth hormone deficiency syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105079076A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1480206A (en) * | 2002-09-02 | 2004-03-10 | 成都浦泓生物科技开发有限公司 | Combination of gadol and Chinese caterpillar fungus as well as preparing method |
| US20080089946A1 (en) * | 2005-11-10 | 2008-04-17 | Olalde Rangel Jose A | Synergistic Phytoceutical Compositions |
| CN101721613A (en) * | 2008-10-14 | 2010-06-09 | 北京因科瑞斯医药科技有限公司 | Composition for enhancing constitution and preparation method thereof |
-
2014
- 2014-05-13 CN CN201410200379.0A patent/CN105079076A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1480206A (en) * | 2002-09-02 | 2004-03-10 | 成都浦泓生物科技开发有限公司 | Combination of gadol and Chinese caterpillar fungus as well as preparing method |
| US20080089946A1 (en) * | 2005-11-10 | 2008-04-17 | Olalde Rangel Jose A | Synergistic Phytoceutical Compositions |
| CN101721613A (en) * | 2008-10-14 | 2010-06-09 | 北京因科瑞斯医药科技有限公司 | Composition for enhancing constitution and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9775868B2 (en) | Traditional Chinese medicine combination for regulating immune function and preparation method therefor | |
| US20130123212A1 (en) | Anti-fatigue composition, formulation and use thereof | |
| TWI678211B (en) | Uses of cistanche tubulosa extract and isoacteoside in protecting muscles | |
| CN111035649B (en) | NMN + GLP compound nutritional supplement and preparation method and application thereof | |
| CN101711810B (en) | Preparation used for improving sleep and enhancing immunity | |
| CN102600212B (en) | Medicinal health product for immunity enhancement and adjuvant treatment of tumor | |
| CN101999663A (en) | Application of traditional Chinese medicine composition in preparation of health food and medicine for alleviating physical fatigue | |
| CN107343658A (en) | A kind of antifatigue SOD oyster peptides complex capsule and preparation method thereof | |
| Heo et al. | The efficacy and safety of Cordyceps militaris in Korean adults who have mild liver dysfunction | |
| TW201338786A (en) | Pharmaceutical composition for preventing and treating liver fibrosis or nonalcoholic fatty liver disease | |
| CN103622027B (en) | A kind of hypoglycemia healthcare food composition | |
| US20240197799A1 (en) | Ganoderma lucidum spore oil and use thereof in preparation of anti-cancer-related fatigue medicaments | |
| CN105079076A (en) | Pharmaceutical composition for the treatment of adult growth hormone deficiency syndrome | |
| CN105999096A (en) | Composition for enhancing immunity and application | |
| WO2010037255A1 (en) | The usage of ginseng and gynostemma pentaphyllum compound preparation in manufacture of medicaments with the effects of lipid regulation and blood-sugar regulation | |
| US10383904B2 (en) | Composition for improving health and quality of life of women containing ginseng berry extract | |
| HK1200370A1 (en) | A taiwanofungus camphorates compound formula and a pharmaceutical composition with the compound formula | |
| TWI626944B (en) | Pharmaceutical composition for the treatment of adult growth hormone deficiency syndrome | |
| CN103830584A (en) | Medicament for treating vertebral artery ischemic disease and preparation method thereof | |
| Semwal et al. | A Review on Ganoderma (King of herbs): Health benefits as health supplements | |
| CN104013680A (en) | Extractive for preparing astragalus membranaceus-ligustrum healthy-qi-reinforcing preparation | |
| CN105616633A (en) | Preparation method of traditional Chinese medicine composition for treating leukopenia after chemotherapy | |
| CN109758559A (en) | A kind of Chinese medicine composition and its preparation method and application for treating chronic fatigue syndrome | |
| CN107927745B (en) | A Chinese medicinal health food composition, and its preparation method and preparation | |
| CN102232957A (en) | Antitumor activities of 3-acetoxyl-8,24-lanostadiene-21-acid and use of 3-acetoxyl-8, 24-lanostadiene-21-acid in medicines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151125 |